Cargando…
A hybrid Forecast Cost Benefit Classification of diabetes mellitus prevalence based on epidemiological study on Real-life patient’s data
The increasing ratio of diabetes is found risky across the planet. Therefore, the diagnosis is important in population with extreme risk of diabetes. In this study, a decision-making classifier (J48) is applied over a data-mining platform (Weka) to measure accuracy and linear regression on classific...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626127/ https://www.ncbi.nlm.nih.gov/pubmed/31300715 http://dx.doi.org/10.1038/s41598-019-46631-9 |
_version_ | 1783434510526840832 |
---|---|
author | Sohail, Muhammad Noman Jiadong, Ren Uba, Musa Muhammad Irshad, Muhammad Iqbal, Wasim Arshad, Jehangir John, Antony Verghese |
author_facet | Sohail, Muhammad Noman Jiadong, Ren Uba, Musa Muhammad Irshad, Muhammad Iqbal, Wasim Arshad, Jehangir John, Antony Verghese |
author_sort | Sohail, Muhammad Noman |
collection | PubMed |
description | The increasing ratio of diabetes is found risky across the planet. Therefore, the diagnosis is important in population with extreme risk of diabetes. In this study, a decision-making classifier (J48) is applied over a data-mining platform (Weka) to measure accuracy and linear regression on classification results to forecast cost/benefit ratio in diabetes mellitus patients along with prevalence. In total 108 invasive and non-invasive medical features are considered from 251 patients for assessment, and the real-time data are gathered from Pakistan over a time span of June 2017 to April 2018. The results indicate that J48 classifiers achieved the best accuracy of (99.28%), whereas, error rate (0.08%), Kappa stats, PRC, and MCC are (0.98%), precision, recall, and F-matrix are (0.99%). In addition, true positive rate is (0.99%) and false positive is (0.08%). The regression forecast decision indicates blood pressure and glucose level are key features for diabetes. The cost/benefit matrix indicates two predictions for positive test with accuracy (66.68%) and (30.60%), and key attributes with total Gain (118.13%). The study confirmed the proposed prediction is practical for screening of diabetes mellitus patients at the initial stage without invasive medical tests and found effectual in the early diagnosis of diabetes. |
format | Online Article Text |
id | pubmed-6626127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-66261272019-07-21 A hybrid Forecast Cost Benefit Classification of diabetes mellitus prevalence based on epidemiological study on Real-life patient’s data Sohail, Muhammad Noman Jiadong, Ren Uba, Musa Muhammad Irshad, Muhammad Iqbal, Wasim Arshad, Jehangir John, Antony Verghese Sci Rep Article The increasing ratio of diabetes is found risky across the planet. Therefore, the diagnosis is important in population with extreme risk of diabetes. In this study, a decision-making classifier (J48) is applied over a data-mining platform (Weka) to measure accuracy and linear regression on classification results to forecast cost/benefit ratio in diabetes mellitus patients along with prevalence. In total 108 invasive and non-invasive medical features are considered from 251 patients for assessment, and the real-time data are gathered from Pakistan over a time span of June 2017 to April 2018. The results indicate that J48 classifiers achieved the best accuracy of (99.28%), whereas, error rate (0.08%), Kappa stats, PRC, and MCC are (0.98%), precision, recall, and F-matrix are (0.99%). In addition, true positive rate is (0.99%) and false positive is (0.08%). The regression forecast decision indicates blood pressure and glucose level are key features for diabetes. The cost/benefit matrix indicates two predictions for positive test with accuracy (66.68%) and (30.60%), and key attributes with total Gain (118.13%). The study confirmed the proposed prediction is practical for screening of diabetes mellitus patients at the initial stage without invasive medical tests and found effectual in the early diagnosis of diabetes. Nature Publishing Group UK 2019-07-12 /pmc/articles/PMC6626127/ /pubmed/31300715 http://dx.doi.org/10.1038/s41598-019-46631-9 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Sohail, Muhammad Noman Jiadong, Ren Uba, Musa Muhammad Irshad, Muhammad Iqbal, Wasim Arshad, Jehangir John, Antony Verghese A hybrid Forecast Cost Benefit Classification of diabetes mellitus prevalence based on epidemiological study on Real-life patient’s data |
title | A hybrid Forecast Cost Benefit Classification of diabetes mellitus prevalence based on epidemiological study on Real-life patient’s data |
title_full | A hybrid Forecast Cost Benefit Classification of diabetes mellitus prevalence based on epidemiological study on Real-life patient’s data |
title_fullStr | A hybrid Forecast Cost Benefit Classification of diabetes mellitus prevalence based on epidemiological study on Real-life patient’s data |
title_full_unstemmed | A hybrid Forecast Cost Benefit Classification of diabetes mellitus prevalence based on epidemiological study on Real-life patient’s data |
title_short | A hybrid Forecast Cost Benefit Classification of diabetes mellitus prevalence based on epidemiological study on Real-life patient’s data |
title_sort | hybrid forecast cost benefit classification of diabetes mellitus prevalence based on epidemiological study on real-life patient’s data |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626127/ https://www.ncbi.nlm.nih.gov/pubmed/31300715 http://dx.doi.org/10.1038/s41598-019-46631-9 |
work_keys_str_mv | AT sohailmuhammadnoman ahybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata AT jiadongren ahybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata AT ubamusamuhammad ahybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata AT irshadmuhammad ahybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata AT iqbalwasim ahybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata AT arshadjehangir ahybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata AT johnantonyverghese ahybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata AT sohailmuhammadnoman hybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata AT jiadongren hybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata AT ubamusamuhammad hybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata AT irshadmuhammad hybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata AT iqbalwasim hybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata AT arshadjehangir hybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata AT johnantonyverghese hybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata |